Not close to an in-person session? Learn more about our live webinars.

If you have been diagnosed with polycythemia vera (PV) or myelofibrosis (MF), you may have questions about the treatment options that are available. The INFOCUS patient education session will provide information about your condition and select treatment options, primarily Jakafi® (ruxolitinib). Join us for a free live session where you will hear from an Incyte Oncology Nurse Educator and meet others like you.

What to expect at the live educational session

Hear from an Incyte Oncology Nurse Educator who may be able to help answer your questions.

Learn LEARN about PV and MF
Connect CONNECT with people like you and learn how to partner with your healthcare professional
Explore EXPLORE some select treatment options, including Jakafi
Discuss DISCUSS the importance of a management plan and setting goals

The speaker will not provide medical advice. Your healthcare professional is the best source of information about your health.
Only your healthcare professional can decide if Jakafi is right for you.

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

UPCOMING SESSIONS

What is Jakafi?

Jakafi is the first and only prescription medicine for treatment of adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is also the first prescription medicine approved to treat adults with intermediate or high-risk myelofibrosis.

FIND A SESSION NEAR YOU

JOIN US!

Please complete and submit the registration form below